| JAK-STAT Signaling Pathway in Pyoderma Gangrenosum (NCT04792957) | Dokuz Eylul University | 2022-05-01 |
| A Novel Therapeutic Treatment of Pyoderma Gangrenosum (NCT05120726) | Louisiana State University Health Sciences Center in New Orleans | 2021-06-02 |
| Phase 0/1 Local Application of the Monoclonal Antibody (Mab) sB24M in Patients With Purulent Pyoderma (NCT04895566) | SWISS BIOPHARMA MED GmbH | 2021-05-24 |
| Secukinumab for the Inflammatory Phase of Pyoderma Gangrenosum (NCT04274166) | Wake Forest University Health Sciences | 2021-05-01 |
| A Study to Assess Adverse Events and Change in Disease State in Adult Participants Being Treated With Humira in Participants Diagnosed With Pyoderma Gangrenosum (PG) (NCT04750213) | AbbVie | 2021-02-12 |
| Exploratory Study of IFX-1 in Patients With Pyoderma Gangrenosum (NCT03971643) | InflaRx GmbH | 2019-05-16 |
| Study on the Clinical Features, Comorbidities and Pathologies Associated With Pyoderma Gangrenosum (NCT03636737) | Assistance Publique Hopitaux De Marseille | 2018-12-01 |
| A Study Assessing the Efficacy and Safety of Adalimumab in Active Ulcer(s) of Pyoderma Gangrenosum in Participants in Japan (NCT03311464) | AbbVie | 2017-10-27 |
| Efficacy and Safety of APD334 in Patients With Pyoderma Gangrenosum (NCT03072953) | Arena Pharmaceuticals | 2017-06-07 |
| An Open-Label, Proof-of-Concept Study of Ixekizumab in the Treatment of Pyoderma Gangrenosum (NCT03137160) | Ohio State University | 2017-05-04 |
| Single-arm Study to Assess a Potential Effect of Anti-IL-17 (Secukinumab) in the Treatment of Pyoderma Gangrenosum (NCT02733094) | Technical University of Munich | 2016-04-01 |
| An Efficacy and Safety Study of Gevokizumab in Treating Active Ulcers of Pyoderma Gangrenosum (NCT02326740) | XOMA (US) LLC | 2014-12-01 |
| A 2-Year, Open-Label, Safety Extension Study of Gevokizumab in Subjects With Pyoderma Gangrenosum (NCT02318914) | XOMA (US) LLC | 2014-11-01 |
| An Efficacy and Safety Study of Gevokizumab in Treating Active Ulcers of Pyoderma Gangrenosum (NCT02315417) | XOMA (US) LLC | 2014-11-01 |
| A Phase II Open Label Study of Xilonix in Subjects With Pyoderma Gangrenosum (NCT01965613) | Janssen Research & Development, LLC | 2014-01-31 |
| Observational Study of the Genetic Architecture of Neutrophil-Mediated Inflammatory Skin Diseases (NCT01952275) | University of Zurich | 2014-01-01 |
| Proof of Concept Study of Gevokizumab in the Treatment of Pyoderma Gangrenosum (NCT01882504) | XOMA (US) LLC | 2013-05-01 |
| Canakinumab for Pyoderma Gangrenosum (NCT01302795) | University of Zurich | 2011-02-01 |
| Safety and Efficacy Study of Humira in Treatment of Pyoderma Gangrenosum (NCT00730717) | Wright State University | 2009-05-01 |
| Study to Determine the Safety and Efficacy of Adalimumab in the Treatment of Pyoderma Gangrenosum (NCT00690846) | Wake Forest University Health Sciences | 2007-07-01 |